Reprogramming to be navigated very cautiously as always. From the first author and team of the now famous 2016 paper in the original post, Prof A. Ocampo.
Parras, A., Vílchez-Acosta, A., Desdín-Micó, G. et al. In vivo reprogramming leads to premature death linked to hepatic and intestinal failure. Nat Aging 3, 1509–1520 (2023). https://doi.org/10.1...587-023-00528-5
https://www.nature.c...587-023-00528-5
"The induction of cellular reprogramming via expression of the transcription factors Oct4, Sox2, Klf4 and c‐Myc (OSKM) can drive dedifferentiation of somatic cells and ameliorate age-associated phenotypes in multiple tissues and organs. However, the benefits of long-term in vivo reprogramming are limited by detrimental side‐effects. Here, using complementary genetic approaches, we demonstrated that continuous induction of the reprogramming factors in vivo leads to hepatic and intestinal dysfunction resulting in decreased body weight and contributing to premature death (within 1 week). By generating a transgenic reprogrammable mouse strain, avoiding OSKM expression in both liver and intestine, we reduced the early lethality and adverse effects associated with in vivo reprogramming and induced a decrease in organismal biological age. This reprogramming mouse strain, which allows longer-term continuous induction of OSKM with attenuated toxicity, can help better understand rejuvenation, regeneration and toxicity during in vivo reprogramming."
